ACADIA Bundle
Who Really Owns ACADIA Pharmaceuticals?
Delving into the ownership of ACADIA Company is vital for anyone tracking the biopharmaceutical sector. Understanding who controls ACADIA Pharmaceuticals reveals insights into its strategic priorities, potential risks, and growth prospects. This analysis is particularly relevant given ACADIA's focus on innovative medicines for central nervous system disorders, a field with significant market potential.
From its inception as Receptor Technologies to its current status as a mid-cap company, ACADIA's ownership has evolved significantly. Knowing who the major shareholders of ACADIA are, along with the influence of ACADIA management, can help investors make informed decisions about ACADIA stock. This exploration will also touch upon the company's financial reports and ACADIA SWOT Analysis, providing a comprehensive view of its market position and future outlook.
Who Founded ACADIA?
The story of ACADIA Pharmaceuticals begins in 1993, initially known as Receptor Technologies. The foundational science is often credited to Dr. Mark R. Brann, but the early team included key figures like Uli Hacksell, who later became CEO and played a vital role in shaping the company's strategic direction. This early phase set the stage for what ACADIA Pharmaceuticals would become.
ACADIA originated in Copenhagen, Denmark, as a subsidiary of Novo Nordisk. Its initial focus was on developing small molecule drugs targeting central nervous system disorders. This early focus was crucial in laying the groundwork for its future endeavors in the pharmaceutical industry.
In 1995, ACADIA transitioned into an independent entity, relocating its headquarters to San Diego, California. This move marked a significant step in its evolution, setting the stage for its growth in the United States. The shift allowed ACADIA to tap into the burgeoning biotech scene in California.
Early Funding Sources
Early funding for ACADIA primarily came from venture capital sources. This funding was essential for fueling the initial research and development efforts before the company went public.
Key Early Investors
Notable early investors included BankInvest, Kommunernes Pensionsforsikring A/S, Dansk Kapitalanlæg Aktieselskab, and private investor Lars Christiansen. These early investors played a crucial role in supporting ACADIA's growth.
Private Placement in 2003
In 2003, ACADIA completed a $25 million private placement of preferred stock. This funding round was led by Oxford Bioscience Partners.
Additional Investors
Additional investments came from OrbiMed Advisors LLC, Federated Kaufmann Fund, LD Pensions, Hambrecht & Quist Capital Management LLC, ABN AMRO Ventures, Carnegie Fund II Biotechbridge, and Dansk Kapitalanlæg Aktieselskab.
Strategic Importance of Funding
This early funding was crucial in advancing drug candidates from initial discovery to clinical development. The financial support enabled ACADIA to progress its research and development efforts.
Headquarters Location
The headquarters of ACADIA is located in San Diego, California. This location is a hub for biotechnology and pharmaceutical companies.
Key Takeaways on ACADIA Company Ownership
Understanding the early ownership structure of ACADIA Pharmaceuticals provides valuable insights into its evolution and strategic direction. Key figures like Dr. Mark R. Brann and Uli Hacksell were instrumental in shaping the company. Early funding from venture capital and strategic investors was critical for advancing its drug candidates. To understand how ACADIA has grown, read about the Growth Strategy of ACADIA.
- ACADIA Pharmaceuticals was initially a subsidiary of Novo Nordisk.
- The company transitioned to an independent entity in 1995.
- Early funding came from venture capital and strategic investors.
- The headquarters is located in San Diego, California.
ACADIA SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has ACADIA’s Ownership Changed Over Time?
The journey of ACADIA Pharmaceuticals, from its inception to its current status, showcases a significant evolution in its ownership structure. The company, which went public in May 2004 through an Initial Public Offering (IPO) on the NASDAQ under the ticker 'ACAD', initially saw Allergan retain a 6.3% ownership stake due to a prior collaboration. The IPO, although originally aiming for approximately $64 million, ultimately raised about $35 million. A subsequent stock offering in May 2007 further bolstered its financial position, adding an additional $102 million.
Over time, the ownership of ACADIA has shifted, with institutional investors becoming the dominant shareholders. This shift is typical for established biopharmaceutical companies and reflects the confidence of large financial entities in the company's potential. As of late 2024 and early 2025, institutional investors hold a substantial portion of the company's stock, approximately 94.5%. This concentration highlights the influence of major financial players in shaping the company's direction and strategy. Understanding the dynamics of ACADIA Company Ownership is crucial for investors and stakeholders alike.
| Event | Date | Impact on Ownership |
|---|---|---|
| Initial Public Offering (IPO) | May 2004 | Public listing; Allergan held 6.3% stake. |
| Subsequent Stock Offering | May 2007 | Raised additional capital. |
| Institutional Investment Growth | Late 2024-Early 2025 | Institutional investors held ~94.5% of the stock. |
As of June 12, 2025, ACADIA Pharmaceuticals Inc. has 637 institutional owners and shareholders, holding a total of 198,012,739 shares. Major shareholders include Baker Bros. Advisors Lp, with 42,878K shares representing 25.62% ownership as of May 21, 2025. Other significant institutional investors include BlackRock, Inc., Vanguard Group Inc, Rtw Investments, Lp (5.10% ownership as of May 21, 2025), and Point72 Asset Management, L.P. (2.78% ownership as of May 21, 2025). For more insights into the company's strategic direction, consider reading about the Growth Strategy of ACADIA.
Key Takeaways on ACADIA Company Ownership
Understanding the ownership structure of ACADIA Pharmaceuticals is crucial for investors and stakeholders.
- Institutional investors hold a significant majority of ACADIA stock.
- Major shareholders include Baker Bros. Advisors Lp, BlackRock, and Vanguard Group Inc.
- The company's ownership has evolved from its IPO in 2004 to its current structure.
- This ownership structure reflects the confidence in ACADIA's future prospects.
ACADIA PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on ACADIA’s Board?
The strategic direction and day-to-day operations of ACADIA Pharmaceuticals are overseen by its executive leadership team and Board of Directors. As of early 2025, the leadership team includes Catherine Owen Adams as Chief Executive Officer, appointed effective September 23, 2024. Other key members include Mark Schneyer, Executive Vice President and Chief Financial Officer, and Srdjan (Serge) Stankovic, M.D., M.S.P.H., President. Understanding the ACADIA Company ownership structure is key for investors.
The ACADIA Company board of directors includes members such as Stephen Biggar, M.D., Ph.D., Julian Baker, Laura Brege, James Daly, Elizabeth Garofalo, M.D., Edmund Harrigan, M.D., Adora Ndu, Pharm.D., J.D., and Catherine Owen Adams. Julian C. Baker, a Managing Partner at Baker Brothers Investments, joined the Board of Directors in December 2015, bringing extensive experience in financing and building life sciences companies. Knowing who owns ACADIA is crucial for understanding its strategic direction.
| Board Member | Title | Affiliation |
|---|---|---|
| Catherine Owen Adams | Chief Executive Officer | ACADIA Pharmaceuticals |
| Julian Baker | Managing Partner | Baker Brothers Investments |
| Laura Brege | Director | Various |
| James Daly | Director | Various |
| Elizabeth Garofalo, M.D. | Director | Various |
| Edmund Harrigan, M.D. | Director | Various |
| Adora Ndu, Pharm.D., J.D. | Director | Various |
| Stephen Biggar, M.D., Ph.D. | Director | Various |
While specific details on dual-class shares or special voting rights are not readily available, the significant institutional ownership, particularly by firms like Baker Bros. Advisors, suggests that these major shareholders likely exert substantial influence through their board representation and voting power. For more information on the competitive landscape, explore the Competitors Landscape of ACADIA.
Key Takeaways on ACADIA's Board and Ownership
The Board of Directors is composed of experienced individuals from various backgrounds, including finance and medicine.
- Catherine Owen Adams is the current CEO.
- Julian Baker's presence on the board indicates significant influence from Baker Brothers Investments.
- Institutional investors likely hold substantial voting power.
- Understanding the board composition is vital for ACADIA investors.
ACADIA Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped ACADIA’s Ownership Landscape?
Over the past few years, several developments have influenced the ownership dynamics of ACADIA Pharmaceuticals. A notable shift occurred on September 23, 2024, with Catherine Owen Adams succeeding Stephen R. Davis as CEO. This change is part of a strategic effort to leverage Ms. Owen Adams' experience in driving company growth. Furthermore, in May 2025, insider trading activity revealed share sales by executives, including Mark C. Schneyer and James Kihara, executed under Rule 10b5-1 trading plans adopted in May 2024.
Institutional investors continue to play a significant role in ACADIA's ownership structure. As of May 2025, institutional holdings increased by 7.8157%. The number of funds or institutions holding positions in ACADIA Pharmaceuticals rose by 9.31% in the last quarter, reaching 634, with total shares owned by institutions increasing by 6.50% to 189,239K shares. Baker Bros. Advisors Lp remains a major holder, owning 25.62% as of May 21, 2025. These trends reflect the ongoing interest and confidence in ACADIA Pharmaceuticals among institutional investors. For more details on how the company operates, you can read about the Revenue Streams & Business Model of ACADIA.
ACADIA's financial performance also provides context for ownership trends. In 2024, total net product sales reached $957.8 million, representing a 32% revenue growth. The first quarter of 2025 saw total revenues of $244.3 million, a 19% year-over-year increase, driven by strong sales of NUPLAZID and DAYBUE. The company projects full-year 2025 total revenue to be between $1.03 billion and $1.095 billion. Analysts are optimistic, with a projected average one-year price target of $24.69/share as of May 6, 2025, suggesting a potential 13.02% upside from its closing price of $21.85/share.
Institutional Ownership
Institutional ownership in ACADIA Pharmaceuticals increased by 7.8157% as of May 2025, with 634 funds or institutions reporting positions, a 9.31% rise in the last quarter.
Financial Performance
Total net product sales reached $957.8 million in 2024, reflecting a 32% revenue growth. Q1 2025 revenues were $244.3 million, up 19% year-over-year.
Leadership Changes
Catherine Owen Adams became CEO on September 23, 2024, succeeding Stephen R. Davis. This change is part of a strategic move to leverage her experience.
Insider Trading
Executives sold shares in May 2025, including Mark C. Schneyer and James Kihara, under Rule 10b5-1 trading plans adopted in May 2024.
ACADIA Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of ACADIA Company?
- What is Competitive Landscape of ACADIA Company?
- What is Growth Strategy and Future Prospects of ACADIA Company?
- How Does ACADIA Company Work?
- What is Sales and Marketing Strategy of ACADIA Company?
- What is Brief History of ACADIA Company?
- What is Customer Demographics and Target Market of ACADIA Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.